AU
CA
NZ
UK
US
IND
Last update at 2026-03-12T05:45:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow
Tue 22 Apr 25, 12:02 PMResmed Names Salli Schwartz as Chief Investor Relations Officer
Mon 21 Apr 25, 09:00 PMEarnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
Mon 21 Apr 25, 02:00 PMWhat Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings
Thu 17 Apr 25, 01:15 PMStrength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?
Tue 08 Apr 25, 12:39 PMQ4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Tue 08 Apr 25, 09:04 AMResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US
Thu 03 Apr 25, 05:28 PMResMed Inc. (RMD): A Bull Case Theory
Thu 03 Apr 25, 01:41 PMResmed Inc. (RMD): Jim Cramer Says He Likes This Sleep Apnea Treatment Stock
Wed 02 Apr 25, 09:35 PMMorgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It
Fri 28 Mar 25, 11:04 AM| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | 1677.57M | 1264.80M | 1101.66M | 960.48M | 883.66M |
| Minority interest | - | - | - | - | - |
| Net income | 1400.72M | 1020.95M | 897.56M | 897.56M | 474.50M |
| Selling general administrative | 991.02M | 917.14M | 874.00M | 739.37M | 670.39M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 3054.97M | 2655.30M | 2355.66M | 2024.31M | 1839.10M |
| Reconciled depreciation | 235.81M | 216.21M | 197.56M | 193.84M | 191.52M |
| Ebit | 1687.39M | 1310.51M | 1141.97M | 1000.29M | 921.02M |
| Ebitda | 1923.20M | 1526.71M | 1339.54M | 1194.13M | 1112.54M |
| Depreciation and amortization | 235.81M | 216.21M | 197.56M | 193.84M | 191.52M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 1685.36M | 1384.12M | 1131.87M | 1000.29M | 903.68M |
| Other operating expenses | 3460.96M | 3365.40M | 3071.00M | 2577.84M | 2284.47M |
| Interest expense | - | 45.71M | - | 0.00000M | 23.99M |
| Tax provision | 276.84M | 243.85M | 204.11M | 181.05M | 409.16M |
| Interest income | 2.54M | 51.60M | 44.72M | 43.00M | 34.83M |
| Net interest income | 4.11M | -45.70800M | -47.37900M | -22.31200M | -23.62700M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 276.84M | 243.85M | 204.11M | 181.05M | 409.16M |
| Total revenue | 5146.33M | 4685.30M | 4222.99M | 3578.13M | 3196.82M |
| Total operating expenses | 1369.61M | 3301.18M | 1203.66M | 1024.03M | 926.75M |
| Cost of revenue | 2091.36M | 2029.99M | 1867.33M | 1553.82M | 1357.72M |
| Total other income expense net | -7.79700M | -73.61500M | -2.95400M | -17.49100M | -5.06200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1400.72M | 1020.95M | 897.56M | 779.44M | 474.50M |
| Net income applicable to common shares | 1400.72M | 1020.95M | 897.56M | 779.44M | 474.50M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 8174.39M | 6872.39M | 6751.71M | 5095.85M | 4728.12M |
| Intangible assets | 3511.54M | 485.90M | 552.34M | 345.94M | 392.58M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 180.01M | 437.02M | 337.91M | 208.15M |
| Total liab | 2206.53M | 2008.35M | 2621.80M | 1735.10M | 1842.45M |
| Total stockholder equity | 5967.86M | 4864.04M | 4129.90M | 3360.75M | 2885.68M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | 485.19M | 875.77M | 779.23M | 1257.12M |
| Common stock | 0.76M | 0.59M | 0.59M | 0.59M | 0.58M |
| Capital stock | - | 0.59M | 0.59M | 0.59M | 0.58M |
| Retained earnings | 6081.49M | 4991.65M | 4253.02M | 3613.74M | 3079.64M |
| Other liab | - | - | 315.19M | 160.03M | 172.55M |
| Good will | - | 2842.05M | 2770.30M | 1936.44M | 1927.90M |
| Other assets | 438.96M | - | 261.31M | 202.29M | 200.66M |
| Cash | - | 238.36M | 227.89M | 273.71M | 295.28M |
| Cash and equivalents | 1209.45M | - | - | 273.71M | 295.28M |
| Total current liabilities | 1019.12M | 910.65M | 758.53M | 689.30M | 911.77M |
| Current deferred revenue | - | 152.55M | 138.07M | 108.67M | 109.61M |
| Net debt | - | 635.57M | 1352.02M | 643.84M | 498.44M |
| Short term debt | - | 35.18M | 31.82M | 31.77M | 35.59M |
| Short long term debt | - | 9.90M | 9.90M | 9.92M | 12.00M |
| Short long term debt total | - | 873.93M | 1579.91M | 917.55M | 793.72M |
| Other stockholder equity | -74.69900M | 123.34M | 148.83M | 59.18M | -1.05700M |
| Property plant equipment | 718.29M | - | 665.81M | 630.50M | 592.07M |
| Total current assets | 3505.61M | 2357.72M | 2367.83M | 1931.48M | 1574.76M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 807.26M | 1078.37M | 565.20M |
| Short term investments | - | - | - | - | - |
| Net receivables | 939.49M | 837.27M | 704.91M | 575.95M | 614.29M |
| Long term debt | 658.39M | 697.31M | 1431.23M | 765.33M | 643.35M |
| Inventory | 927.71M | 822.25M | 998.01M | 743.91M | 457.03M |
| Accounts payable | - | 237.73M | 150.76M | 159.25M | 138.01M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -251.52900M | -272.52800M | -312.74700M | -193.48700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | -1623.25600M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | 284.00M | 395.43M | 251.49M | 240.82M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | - | 4514.68M | 4383.88M | 3164.38M | 3153.37M |
| Capital lease obligations | - | 166.72M | 138.77M | 142.31M | 138.36M |
| Long term debt total | 658.39M | - | - | 765.33M | 643.35M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -200.04500M | -269.78400M | -1159.84500M | -13.92200M | -21.78800M |
| Change to liabilities | - | - | 31.34M | -247.63200M | 210.71M |
| Total cashflows from investing activities | -200.04500M | -269.78400M | -1159.84500M | -229.91800M | -158.46200M |
| Net borrowings | -40.00000M | -730.00000M | 665.00M | 122.00M | -522.00000M |
| Total cash from financing activities | -606.25300M | -1119.28700M | 422.87M | -128.36300M | -764.63200M |
| Change to operating activities | - | - | -138.12500M | -168.10900M | -58.15400M |
| Net income | 1400.72M | 1020.95M | 897.56M | 779.44M | 474.50M |
| Change in cash | 971.09M | 10.47M | -45.81900M | -21.56800M | -167.87800M |
| Begin period cash flow | 238.36M | 227.89M | 273.71M | 295.28M | 463.16M |
| End period cash flow | 1209.45M | 238.36M | 227.89M | 273.71M | 295.28M |
| Total cash from operating activities | 1751.59M | 1401.26M | 693.30M | 351.15M | 736.72M |
| Issuance of capital stock | 74.44M | 53.09M | 49.14M | 47.38M | 37.79M |
| Depreciation | 235.81M | 216.21M | 197.56M | 193.84M | 191.52M |
| Other cashflows from investing activities | -10.77700M | -15.39600M | -1025.84500M | -17.17600M | 19.22M |
| Dividends paid | -310.88000M | -282.32000M | -258.27600M | 245.34M | -245.34100M |
| Change to inventory | -80.16500M | 172.20M | -248.83300M | -311.68100M | -21.95400M |
| Change to account receivables | -76.68400M | -134.27800M | -106.51100M | 19.35M | -129.19500M |
| Sale purchase of stock | -300.02500M | -150.01100M | 1070.00M | 288.00M | 90.00M |
| Other cashflows from financing activities | -29.78700M | -10.05000M | -32.99200M | -52.40600M | -53.70900M |
| Change to netincome | - | - | 60.31M | 85.94M | 74.39M |
| Capital expenditures | 100.64M | 114.86M | 134.00M | 156.04M | 116.83M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 16.74M | 44.78M | -462.12700M | -708.07600M | 1.41M |
| Stock based compensation | 91.66M | 80.18M | 71.14M | 65.26M | 65.26M |
| Other non cash items | 6.66M | 39.13M | -11.05000M | 20.69M | 8.67M |
| Free cash flow | 1650.95M | 1286.40M | 559.30M | 195.11M | 619.89M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RMD Resmed Inc |
-1.07 3.13% | 33.14 | 25.80 | 21.88 | 9.89 | 5.95 | 6.86 | 17.74 |
| FPH Fisher & Paykel Healthcare Corporation Ltd |
-0.01 0.03% | 31.87 | 55.29 | 45.45 | 9.33 | 12.10 | 16.65 | 32.34 |
| ANN Ansell Ltd |
0.01 0.03% | 29.80 | 23.37 | 19.46 | 2.20 | 1.64 | 1.90 | 12.60 |
| NAN Nanosonics Ltd |
-0.09 2.50% | 3.51 | 49.00 | 46.30 | 5.02 | 4.47 | 4.00 | 26.19 |
| SDI SDI Ltd |
-0.005 0.40% | 1.25 | 12.65 | 5.06 | 1.35 | 1.45 | 1.45 | 7.89 |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD | Founder & Non-Exec. Chairman | 1942 |
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Director | 1972 |
| Mr. Robert A. Douglas | Pres & COO | 1960 |
| Mr. Brett A. Sandercock | Chief Financial Officer | 1967 |
| Mr. David B. Pendarvis | Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. | 1959 |
| Mr. Kaushik Ghoshal | Pres of SaaS Bus. | 1968 |
| Ms. Urvashi Tyagi | Chief Technology Officer | NA |
| Ms. Constance C. Bienfait | Director of Investor Relations | NA |
| Ms. Amy Wakeham | VP of Investor Relations & Corp. Communications | NA |
| Ms. Vered Keisar | Chief People Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...